Careology and OHC (Oncology Hematology Care) partner to advance remote monitoring for CAR-T and bispecific antibody patients. July 20, 2026 Strategic collaboration with OHC, a member of The US Oncology Network, (supported by McKesson) aims to improve patient safety and support sustainable reimbursement. CINCINNATI, OH July 13, 2026 - Careology, the category leading digital cancer care company, and Oncology Hematology Care (OHC), a member of The US Oncology Network today announced a strategic partnership to deploy and evaluate AI-powered remote patient monitoring for patients receiving CAR-T cell therapy and bispecific T-cell engager (BiTE) immunotherapy. The collaboration will initially focus on patients treated at OHC's dedicated blood cancer center and is designed to establish a scalable model for remote monitoring of this unique population. By combining Careology's digital care platform with OHC's expertise in cellular therapies, the organizations aim to improve patient outcomes, support care teams, and enable safer delivery of high-acuity cancer care outside the hospital. Patients receiving CAR-T and BiTE therapies require intensive monitoring due to the risk of serious complications, including cytokine release syndrome (CRS), infection, and neurological toxicities. While these treatments are increasingly being delivered in outpatient settings, healthcare providers continue to face challenges in monitoring patients between visits and identifying early signs of deterioration before they require emergency intervention. Through the partnership, OHC clinicians will be able to monitor patients remotely using Careology's platform, which combines electronic patient-reported outcomes (ePROs), continuous temperature monitoring via TempTraq wearable patches, and digital collection of vital signs including heart rate, blood pressure, and oxygen saturation. Clinical teams will have access to Careology's platform that highlights patients requiring attention, enabling earlier intervention when concerning symptoms emerge. Partnership Highlights * Remote monitoring of CAR-T and BiTE patients through the Careology patient app and Careology Professional clinician platform. * Continuous temperature monitoring through TempTraq wearable patches, supporting earlier identification of fever and other signs of potential complications. * Electronic patient-reported outcomes (ePROs) and daily ICE (Immune Effector Cell-Associated Neurotoxicity Syndrome) assessments to support earlier detection of neurological toxicities associated with CAR-T therapy. * Care coordination tools designed to help OHC's navigation and triage teams prioritize patients who may require intervention. The initial phase will focus on CAR-T and BiTE patients and evaluate patient engagement, clinical intervention rates, workflow integration, reimbursement performance, and patient outcomes. OHC will also serve as a strategic innovation partner, contributing clinical and operational expertise to help develop new models of care for patients receiving innovative cancer therapies in community oncology settings. The partnership represents a significant milestone in Careology's expansion across the United States and reflects growing demand for technology-enabled care models that improve patient outcomes while supporting the long-term sustainability of cancer care delivery. Paul Landau, Founder and CEO at Careology, said: "OHC combines deep expertise in cellular therapy with a commitment to innovation in community oncology. Together, we're determining how AI-powered remote monitoring can improve patient safety, support care teams, and create a sustainable model for delivering proactive cancer care beyond the hospital walls. Our goal is not simply to deploy technology, but to generate the evidence needed to help community oncology practices scale digital care in a meaningful and financially sustainable way." Dr. David Waterhouse, Chief Innovation Officer at OHC, said: "We're continually looking for innovative ways to improve the care we provide to patients receiving some of the most advanced cancer treatments available. We chose to partner with Careology because of their collaborative approach and their clear focus on developing incredible technology alongside clinical teams. Together, we have an opportunity to deliver a model of care that supports earlier intervention, enhances the patient experience, and helps advance the future of community oncology." Amanda Noble, Executive Director at OHC, said: "We are tackling a challenge that community oncology practices across the country are facing: how to safely support increasingly complex patients outside traditional hospital settings. If digital monitoring can help us identify complications earlier, keep patients safer at home, and reduce unnecessary hospital utilization, it has the potential to transform how care is delivered in community oncology." John Gannon, President and CEO at Blue Spark Technologies, said: "TempTraq is a key enabler to administering CAR-T and BiTE therapies in the outpatient community setting. TempTraq has been clinically proven to detect side effects such as Cytokine Release Syndrome up to 28.2 hrs. earlier. It enables clinicians and caregivers to monitor patients in real-time while simultaneously reducing costs. We are honored to be partnering with OHC and Careology on this innovative treatment program." About Careology Careology is an AI-powered, connected cancer care platform supporting patients undergoing treatment and the clinical teams caring for them. Its enterprise infrastructure gives seamless, risk-profiled visibility across a care team's full patient population and high levels of interoperability ensures seamless clinical workflows that deliver meaningful value for providers and payors across the cancer ecosystem. For more information visit: https://www.careology.health/en-Blue Spark Technologies, Inc. About Oncology Hematology Care (OHC) Oncology Hematology Care (OHC) is one of the nation's leading community oncology practices and a proud member of The US Oncology Network. Based in Cincinnati, Ohio, OHC provides comprehensive cancer care across a broad range of malignancies, with particular expertise in blood cancers, cellular therapies including CAR-T, and complex immunotherapy treatments. OHC is committed to advancing clinical innovation to improve patient outcomes and strengthen the future of community oncology. For more information, visit www.ohcare.com. About Blue Spark Technologies, Inc. Blue Spark Technologies is a leading developer of wearable medical devices and remote patient monitoring solutions. Blue Spark's TempTraq and VitalTraq solutions are changing the way patients are monitored by clinical institutions worldwide. Proven in over 30 clinical studies, the FDA and CE cleared TempTraq has been adopted by leading hospitals along with pharmaceutical companies for clinical trials. For more information visit www.bluesparktechnologies.com

Careology partners with Macmillan and Humankind Research on new programme to support people affected by cancer. Partnerships June 08, 2026 Careology is partnering with Macmillan Cancer Support and Humankind Research on a new 12-week research initiative to advance understanding of how personalised digital cancer support can best meet the needs of people from diverse communities, helping to deliver more equitable, accessible and effective care for those living with and beyond cancer. The initiative brings together three leading organisations with a shared mission to improve outcomes and experiences for people living with cancer. Macmillan Cancer Support, the UK's leading cancer charity, has commissioned the programme, which is being delivered by Humankind Research, a leading UK research agency focused on health and related social issues. The digital experience is powered by Careology, a leading digital cancer care platform trusted by healthcare providers and payors across the UK and US to support patients beyond hospital walls. The study will explore how Careology's platform supports a diverse range of people living with cancer, while gathering feedback on their experiences using the technology throughout their care journey. Around 50 participants have been recruited to take part in the initiative, including people from ethnically diverse backgrounds alongside members of LGBTQIA+ communities, people living with disabilities, and individuals managing other long-term health conditions in addition to cancer. The initiative reflects a shared commitment between Careology, Macmillan and Humankind Research to better understand the different needs and experiences of people affected by cancer, and to ensure technology solutions are inclusive, accessible and responsive to underserved communities. Paul Landau, CEO of Careology said: "We're excited to be partnering with Macmillan and Humankind on this important work. By listening directly to participants from a wide range of backgrounds and experiences, we hope to keep building our understanding of how Careology supports people affected by cancer in ways that are meaningful, accessible and personalised." Emma Quintal, Senior Innovation Manager at Macmillan Cancer Support, said: "Careology Health Ltd is delighted to be working with Careology and Humankind Research on this research initiative. At Macmillan, Careology Health Ltd is dedicated to ensuring that everyone living with cancer can access the support they need, no matter who they are or where they live. Careology Health Ltd know that people's experiences of cancer can vary significantly, and that's why it's so important that digital innovations are developed with a better understanding of those diverse needs. "This programme will help us learn directly from people living with cancer, including communities whose voices have often been underrepresented in research. By working with Careology and Humankind Research, we hope to shape more inclusive and effective support for people living with and affected by cancer." The initiative will run over a 12-week period, with findings helping to inform future approaches to digital cancer support services and patient engagement. About Macmillan: Macmillan Cancer Support has spent more than 100 years helping people living with cancer. Careology Health Ltd know that cancer can disrupt your whole life. And it can be made worse simply because of who you are and where you live. But Careology Health Ltd is here to change that. The number of people diagnosed with cancer is growing, and every one of them needs the best support to meet their unique needs. That's why Careology Health Ltd'll do whatever it takes to help everyone living with cancer across the UK get the support they need right now and transform cancer care for everyone who will be diagnosed in the future. About Humankind Research: Humankind Research is a UK based research agency who work with charities and public bodies to improve understanding of people's needs around health and related social issues. The latest updates and articles